Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review

被引：2

作者：

Kraev, Krasimir ^{[1
]}

Geneva-Popova, Mariela Gencheva ^{[1
]}

Hristov, Bozhidar Krasimirov ^{[2
]}

Uchikov, Petar Angelov ^{[3
]}

Belova-Popova, Stanislava Dimitrova ^{[1
]}

Kraeva, Maria Ilieva ^{[4
]}

Basheva-Kraeva, Yordanka Mincheva ^{[5
]}

Stoyanova, Nina Staneva ^{[5
]}

Mitkova-Hristova, Vesela Todorova ^{[5
]}

Koleva-Ivanova, Maria Stoyanova ^{[6
]}

Taneva, Daniela Ivova ^{[7
]}

Ivanov, Atanas Slavchev ^{[8
]}

机构：

[1] Med Univ Plovdiv, Med Fac, Dept Propedeut Internal Dis, Plovdiv 4000, Bulgaria

[2] Med Univ Plovdiv, Med Fac, Dept Internal Dis 2, Plovdiv 6000, Bulgaria

[3] Med Univ Plovdiv, Med Fac, Dept Special Surg, Plovdiv 6000, Bulgaria

[4] Med Univ Plovdiv, Med Fac, Dept Otorhynolaryngol, Plovdiv 6000, Bulgaria

[5] Med Univ Plovdiv, Univ Eye Clin, Univ Hosp, Dept Ophthalmol,Fac Med, Plovdiv 4000, Bulgaria

[6] Med Univ Plovdiv, Fac Med, Dept Gen & Clin Pathol, Plovdiv 4000, Bulgaria

[7] Med Univ Plovdiv, Fac Publ Hlth, Dept Nursing Care, Plovdiv 4000, Bulgaria

[8] Med Univ Plovdiv, Dept Urol & Gen Med, Plovdiv 4000, Bulgaria

来源：

LIFE-BASEL | 2023年 / 13卷 / 12期

关键词：

JAK inhibitors; immune-mediated diseases; safety profile; adverse events; RHEUMATOID-ARTHRITIS; VENOUS THROMBOEMBOLISM; ALOPECIA-AREATA; TOFACITINIB; RISK; EFFICACY; METHOTREXATE; METAANALYSIS; BARICITINIB; PSORIASIS;

D O I：

10.3390/life13122244

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE), remain a focus of extensive research and clinical scrutiny. This comprehensive literature review embarks on an exploration of the multifaceted landscape of JAK inhibitors, providing insights into their safety profiles across diverse immune-mediated diseases. The introduction highlights the transformative influence of JAK inhibitors in the treatment of immune-mediated diseases. Historically, the therapeutic arsenal for these conditions included corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologics. The advent of JAK inhibitors has revolutionized this landscape, although concerns about their safety persist. This review strives to comprehensively evaluate their safety, amalgamating knowledge from multiple studies and trials. The subsequent sections delve into the safety of specific JAK inhibitors in the context of rheumatoid arthritis, inflammatory bowel diseases, and dermatologic conditions and their associations with venous thromboembolism. The evolving understanding of TE risk, particularly the intricate relationship between these agents and immune-mediated diseases, is meticulously unravelled. The concluding remarks underscore the dynamic nature of TE risk assessment with regard to immune-mediated diseases involving JAK inhibitors. It underscores that risk assessment is multifactorial, influenced not only by the choice of JAK inhibitor but also by the nuances of the underlying immune-mediated disease and the unique patient characteristics. This review offers a holistic perspective on TE risks associated with JAK inhibitors and contributes to the ongoing dialogue regarding their safety in the realm of immune-mediated diseases.

引用

页数：18

共 56 条

[1] Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3 [J].

Aletaha, Daniel ;

Westhovens, Rene ;

Gaujoux-Viala, Cecile ;

Adami, Giovanni ;

Matsumoto, Alan ;

Bird, Paul ;

Messina, Osvaldo Daniel ;

Buch, Maya H. ;

Bartok, Beatrix ;

Yin, Zhaoyu ;

Guo, Ying ;

Hendrikx, Thijs ;

Burmester, Gerd R. .

RMD OPEN, 2021, 7 (02)

[2] The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors [J].

Bechman, Katie ;

Yates, Mark ;

Galloway, James B. .

PHARMACOLOGICAL RESEARCH, 2019, 147

[3] Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis [J].

Bezzio, Cristina ;

Vernero, Marta ;

Ribaldone, Davide Giuseppe ;

Alimenti, Eleonora ;

Manes, Gianpiero ;

Saibeni, Simone .

CANCERS, 2023, 15 (08)

[4] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial [J].

Bissonnette, R. ;

Iversen, L. ;

Sofen, H. ;

Griffiths, C. E. M. ;

Foley, P. ;

Romiti, R. ;

Bachinsky, M. ;

Rottinghaus, S. T. ;

Tan, H. ;

Proulx, J. ;

Valdez, H. ;

Gupta, P. ;

Mallbris, L. ;

Wolk, R. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) :1395-1406

[5] Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis [J].

Burmester, Gerd R. ;

Cohen, Stanley B. ;

Winthrop, Kevin L. ;

Nash, Peter ;

Irvine, Alan D. ;

Deodhar, Atul ;

Mysler, Eduardo ;

Tanaka, Yoshiya ;

Liu, John ;

Lacerda, Ana P. ;

Palac, Hannah ;

Shaw, Tim ;

Mease, Philip J. ;

Guttman-Yassky, Emma .

RMD OPEN, 2023, 9 (01)

[6] Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme [J].

Cohen, Stanley B. ;

Tanaka, Yoshiya ;

Mariette, Xavier ;

Curtis, Jeffrey R. ;

Lee, Eun Bong ;

Nash, Peter ;

Winthrop, Kevin L. ;

Charles-Schoeman, Christina ;

Wang, Lisy ;

Chen, Connie ;

Kwok, Kenneth ;

Biswas, Pinaki ;

Shapiro, Andrea ;

Madsen, Ann ;

Wollenhaupt, Juergen .

RMD OPEN, 2020, 6 (03)

[7]

Cohen SB, 2021, ANN RHEUM DIS, V80, P304, DOI [10.1136/annrheumdis-2020-218510, 10.1136/annrheumdis-2020-218510.]

[8] Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial [J].

Combe, Bernard ;

Kivitz, Alan ;

Tanaka, Yoshiya ;

van der Heijde, Desiree ;

Simon, J. Abraham ;

Baraf, Herbert S. B. ;

Kumar, Uma ;

Matzkies, Franziska ;

Bartok, Beatrix ;

Ye, Lei ;

Guo, Ying ;

Tasset, Chantal ;

Sundy, John S. ;

Jahreis, Angelika ;

Genovese, Mark C. ;

Mozaffarian, Neelufar ;

Landewe, Robert B. M. ;

Bae, Sang-Cheol ;

Keystone, Edward C. ;

Nash, Peter .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07) :848-858

[9] Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata [J].

Crispin, Milene Kennedy ;

Ko, Justin M. ;

Craiglow, Brittany G. ;

Li, Shufeng ;

Shankar, Gautam ;

Urban, Jennifer R. ;

Chen, James C. ;

Cerise, Jane E. ;

Jabbari, Ali ;

Winge, Marten C. G. ;

Marinkovich, M. Peter ;

Christiano, Angela M. ;

Oro, Anthony E. ;

King, Brett A. .

JCI INSIGHT, 2016, 1 (15)

[10] Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia [J].

Deakin, Claire T. ;

De Stavola, Bianca L. ;

Littlejohn, Geoffrey ;

Griffiths, Hedley ;

Ciciriello, Sabina ;

Youssef, Peter ;

Mathers, David ;

Bird, Paul ;

Smith, Tegan ;

O'Sullivan, Catherine ;

Freeman, Tim ;

Segelov, Dana ;

Hoffman, David ;

Seaman, Shaun R. .

JAMA NETWORK OPEN, 2023, 6 (06) :E2320851

← 1 2 3 4 5 6 →